The global human immunodeficiency virus therapeutics market size is estimated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the wide prevalence of human immunodeficiency virus cases as well as high death rate of the disease across the world.
The human immunodeficiency virus (HIV) is a type of retrovirus that leads to cause acquired immunodeficiency syndrome (AIDS). In general, the immune cells of HIV patient are normally weakened by the virus, which makes the body vulnerable and unable to fight against the virus and the disease keeps spreading in the body. The disease is contracted when the infected person’s blood is transferred to a normal person or sexual contact with infected person or through sharing of needles with infected person. In some cases, a child can be infected with the disease if the child’s mother got HIV infection during her pregnancy. The symptoms of HIV infection are swollen glands, fatigue, muscle pains, slight fever, and headaches. The infection has no definite treatment but there are therapies that can help reduce or stabilize the infection, which ultimately can prevent suffering from AIDS. According to the 2020 report by the World Health Organization (WHO), nearly 36.3 million deaths were recorded so far across the world due to HIV and by the end of 2020, there were around 37.7 million active cases of HIV worldwide.
The COVID-19 pandemic outbreak had impacted a huge setback in of the global economy and shattered several business operations due to movement restriction and nationwide lockdowns. The pandemic also largely affected the market due to sudden shift of focus to COVID cases by pharmaceutical companies and various governmental organizations. However, as the COVID cases started increasingly subsided across the globe in the mid-2021, the growth rate of the market is expected to get back on the right track.
Market Trends, Drivers, Restraints, and Opportunities
- Several government initiatives to control the disease using methods and campaigns to increase the awareness of the disease among the population are boosting the market growth.
- New drug discoveries as well as extensive research activities on the disease therapeutics are expected to propel the market expansion during the forecast period.
- Rapid introduction of advanced disease diagnosis technique and rising number of people preferring for early diagnosis are major factors fueling up the market growth.
- Presence of wide networking from non-governmental organizations towards the prevention of the disease spread and disease awareness is also bolstering the market growth.
- High cost of the treatment and social stigma around the disease are main factors hindering the market development.
- The rising prevalence of disease along with research & development activities in the field is offering huge opportunities for the market expansion during the forecast period.
Scope of the Report
The report on the global human immunodeficiency virus therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Human Immunodeficiency Virus Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Drugs Class (Nucleoside-analog Reverse Transcriptase Inhibitors, Non-nucleoside Reverse Transcriptase Inhibitors, Entry & Fusion Inhibitors, Protease Inhibitors, Integrase Inhibitors, and Coreceptor Antagonists)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
AbbVie, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Co.; Boehringer Ingelheim GmbH; Genentech, Inc.; and Cipla, Inc.
Market Segment Insights
Nucleoside-analog reverse transcriptase inhibitors segment to grow at a rapid pace
Based on drugs class, the global human immunodeficiency virus therapeutics market is divided into protease inhibitors, nucleoside-analog reverse transcriptase inhibitors, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry & fusion inhibitors, and coreceptor antagonists. The nucleoside-analog reverse transcriptase inhibitors segment is expected to grow at a rapid pace during the projected period owing to the availability of large number of the drugs under this class and these drugs are found to be showing good results for the treatment. The therapy involves the use of combination of drugs to reduce the viral load in the body of the patient.
North America is anticipated to constitute a major market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a major market share during the projected period owing to high prevalence of disease, extensive R&D activities, presence of skilled professionals, and heavy investments by the key players in the region. Additionally, high approval rate of the HIV drugs and better awareness in the population in the region are key drivers of the regional market growth.
On the other hand, the market of Asia Pacific is estimated to register a significant growth rate during the projected period attributed to the high frequency of disease as well as several initiatives taken by governments for disease control and awareness in the region. Meanwhile, the market of Middle East & Africa is projected to hold a considerable market share in the coming years as the region has witnessed tremendous growth opportunities in the coming time due to great number of cases reported in the region.
Segments Covered in the Report
The global human immunodeficiency virus therapeutics market has been segmented on the basis of
- Nucleoside-analog Reverse Transcriptase Inhibitors
- Non-nucleoside Reverse Transcriptase Inhibitors
- Entry & Fusion Inhibitors
- Protease Inhibitors
- Integrase Inhibitors
- Coreceptor Antagonists
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- AbbVie, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb Co.
- Boehringer Ingelheim GmbH
- Genentech, Inc.
- Cipla, Inc.
Key players competing in the global human immunodeficiency virus therapeutics market are AbbVie, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Co.; Boehringer Ingelheim GmbH; Genentech, Inc.; and Cipla, Inc. High investments by these players in the development of new drug and disease therapeutics are boosting the overall market expansion globally.